Valuation: Compugen Ltd.

Market Cap 19Cr 17Cr 15Cr 14Cr 26Cr 1.76TCr 27Cr 183.87Cr 72Cr 919.5Cr 70Cr 68Cr 2.93TCr P/E 2026 *
-7x
P/E 2027 * -7.1x
Enterprise Value 19Cr 17Cr 15Cr 14Cr 26Cr 1.76TCr 27Cr 183.87Cr 72Cr 919.5Cr 70Cr 68Cr 2.93TCr EV / Sales 2026 *
20.1x
EV / Sales 2027 * 24x
Free-Float
99.66%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Compugen Ltd.

1 day-5.77%
1 week-7.98%
Current month-17.65%
1 month-20.33%
3 months-17.30%
6 months-30.50%
Current year+28.10%
1 week 1.93
Extreme 1.93
2.13
1 month 1.93
Extreme 1.93
2.5
Current year 1.51
Extreme 1.51
3.24
1 year 1.43
Extreme 1.43
3.24
3 years 0.53
Extreme 0.53
3.24
5 years 0.51
Extreme 0.51
7.48
10 years 0.51
Extreme 0.51
19.9
Manager TitleAgeSince
Chief Executive Officer - 23/09/2025
Director of Finance/CFO 42 15/08/2024
Chief Operating Officer 49 01/01/2024
Director TitleAgeSince
Chairman 59 23/09/2025
Director/Board Member 59 11/06/2018
Director/Board Member 70 11/06/2018
Date Insider Type Main position Quantity % Market Cap. Importance
29/07/26 Free

Chief Operating Officer

70,000 0.0740%
29/07/26 Free

Chairman

1,00,000 0.1058%
29/07/26 Free

Chief Financial Officer

45,500 0.0481%
Change 5-day change 1-year change 3-year change Capi.($)
-5.77%-7.98%+4.53%+133.47% 19Cr
-6.60%-8.56%+49.38%+63.51% 6.5TCr
+0.03%+5.56%+9.10%+69.05% 5.12TCr
-4.09%-0.11%+2.22%+53.15% 5.12TCr
-1.53%+2.70%+30.48%+34.12% 4.39TCr
-1.34%+4.12%+16.64%+115.13% 4.2TCr
-5.97%-6.22%+228.95%+454.22% 3.81TCr
+6.53%+8.02%+16.40%+53.41% 3.32TCr
-0.90%-10.49%+37.09%-3.70% 2.52TCr
-1.07%+2.33%+19.43%+9.98% 2.25TCr
Average -2.07%-1.11%+41.42%+98.23% 3.73TCr
Weighted average by Cap. -2.20%-0.50%+44.23%+96.55%

Financials

2026 *2027 *
Net sales 92.39L 82.13L 76.12L 69.26L 1.31Cr 88Cr 1.33Cr 9.15Cr 3.59Cr 46Cr 3.47Cr 3.39Cr 145.87Cr 77.5L 68.89L 63.85L 58.09L 1.1Cr 74Cr 1.11Cr 7.68Cr 3.01Cr 38Cr 2.91Cr 2.85Cr 122.36Cr
Net income -2.65Cr -2.35Cr -2.18Cr -1.98Cr -3.74Cr -251.17Cr -3.8Cr -26Cr -10Cr -131.07Cr -9.93Cr -9.72Cr -417.83Cr -2.7Cr -2.4Cr -2.22Cr -2.02Cr -3.81Cr -255.78Cr -3.87Cr -27Cr -10Cr -133.48Cr -10Cr -9.9Cr -425.5Cr
Net Debt - -
Projected Income Statement - Annual - Compugen Ltd.
Logo Compugen Ltd.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Employees
75
Date Price Change Volume
16/26/16 $1.960 -5.77% 1,73,435
15/26/15 $2.080 +4.00% 2,00,141
14/26/14 $2.000 +1.01% 3,78,142
13/26/13 $1.980 -4.35% 2,23,637
12/26/12 $2.070 -2.82% 86,472
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Compugen Ltd.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.960USD
Average target price
4.600USD
Spread / Average Target
+134.69%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Compugen Ltd.
  1. Stock Market
  2. Stocks
  3. CGEN Stock